Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23342709 | 1.00 | MAPT (0.38) | MAPTALDH1A1PIN1SMN1; SMN2HTT | |
| SCHEMBL26290678 | 1.00 | MAPT (0.38) | MAPTALDH1A1PIN1SMN1; SMN2HTT | |
| SCHEMBL15496981 | 0.86 | ALDH1A1 (0.31) | MAPTALDH1A1PIN1 | |
| SCHEMBL8235145 | 0.84 | EPHX1 (0.33) | MAPTALDH1A1PIN1 | |
| SCHEMBL17999802 | 0.84 | EPHX1 (0.33) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL12137048 | 0.78 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL8235170 | 0.76 | — | — | |
| SCHEMBL2138807 | 0.75 | SMN1; SMN2 (0.34) | MAPTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL18819113 | 0.74 | ALDH1A1 (0.35) | MAPTALDH1A1PIN1SMN1; SMN2HTT | |
| SCHEMBL13043754 | 0.73 | MAPT (0.42) | MAPTALDH1A1PIN1SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024017977-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2024-01-25 | — | — | WO | disclosed |
| US-20230381182-A1 | Biomarkers Related to Immune Checkpoint Inhibitor Therapy and Methods of Using the Same | SAIL BIOMEDICINES, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11787771-B2 | Hydrazide containing nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230295131-A1 | INHIBITORS OF RHO-ASSOCIATED COILED-COIL KINASE | ANGION BIOMEDICA CORP. | 2023-09-21 | — | — | US | disclosed |
| US-20230295152-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS | SENDA BIOSCIENCES, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295131-A1 | INHIBITORS OF RHO-ASSOCIATED COILED-COIL KINASE | ANGION BIOMEDICA CORP. | 2023-09-21 | — | — | US | disclosed |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| US-11718616-B2 | JAK kinase inhibitor compounds for treatment of respiratory disease | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-08 | — | — | US | disclosed |
| US-20080113977-A1 | Mixed Lineage Kinase Modulators | ELI LILLY AND COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-20080113977-A1 | Mixed Lineage Kinase Modulators | ELI LILLY AND COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-20080090811-A1 | Carbamate compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-04-17 | — | — | US | disclosed |
| US-7329752-B2 | Carbamate compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7317022-B2 | Benzoimidazolone-carboxamide compounds as 5-HT4 receptors agonists | THERAVANCE, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-7309708-B2 | Hepatitis C virus inhibitors | BIRSTOL-MYERS SQUIBB COMPANY (US) | 2007-12-18 | — | — | US | disclosed |
| US-20070117796-A1 | Carbamate compounds as 5-HT4 receptor agonists | THERAVANCE, INC. | 2007-05-24 | — | — | US | disclosed |
| US-7160907-B2 | Pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-01-09 | — | — | US | disclosed |
| US-7160907-B2 | Pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-01-09 | — | — | US | disclosed |
| US-20060276482-A1 | Benzoimidazolone-carboxamide compounds as 5-HT4 receptors agonists | THERAVANCE, INC. | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276482-A1 | Benzoimidazolone-carboxamide compounds as 5-HT4 receptors agonists | HTR4, HTR5A, HTR1A | MAPT 2952/4885ALDH1A1 2503/4885PIN1 3948/4885 |
| US-20230295152-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS | AHR, ARNT, AIPL1 | MAPT 4722/4885ALDH1A1 162/4885PIN1 1619/4885 |
| US-11718616-B2 | JAK kinase inhibitor compounds for treatment of respiratory disease | JAK1, JAK2, JAK3 | MAPT 3850/4885ALDH1A1 2782/4885PIN1 2605/4885 |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | EP300, KAT2A, KAT6A | MAPT 295/4885ALDH1A1 2786/4885PIN1 4523/4885 |
| US-20230381182-A1 | Biomarkers Related to Immune Checkpoint Inhibitor Therapy and Methods of Using the Same | AHR, CD274, ARNT | MAPT 4740/4885ALDH1A1 208/4885PIN1 1670/4885 |
| US-20070117796-A1 | Carbamate compounds as 5-HT4 receptor agonists | HTR4, HTR1A, HTR2B | MAPT 3716/4885ALDH1A1 2518/4885PIN1 4693/4885 |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | MAPK6, MAP3K6, MAPK4 | MAPT 2731/4885ALDH1A1 2765/4885PIN1 2816/4885 |
| US-20080090811-A1 | Carbamate compounds as 5-HT4 receptor agonists | HTR4, HTR1A, HTR2B | MAPT 3716/4885ALDH1A1 2518/4885PIN1 4693/4885 |
| US-11787771-B2 | Hydrazide containing nuclear transport modulators and uses thereof | XPO1, KPNA1, ABCB11 | MAPT 1292/4885ALDH1A1 1813/4885PIN1 271/4885 |
| US-20230295131-A1 | INHIBITORS OF RHO-ASSOCIATED COILED-COIL KINASE | ROCK1, ROCK2, RHOA | MAPT 531/4885ALDH1A1 3878/4885PIN1 4482/4885 |
| US-20080113977-A1 | Mixed Lineage Kinase Modulators | MYLK2, CSNK1G2, CSNK1A1 | MAPT 4196/4885ALDH1A1 3779/4885PIN1 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.